Avalo Therapeutics (AVTX) CMO receives 43,500-share performance award

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. reported that its Chief Medical Officer, Mittie Doyle, acquired 43,500 shares of Common Stock through a compensation-related award. The transaction was coded as a grant or award, with a price per share of $0.0000, indicating no cash purchase.

Following this award, Doyle directly holds 47,122 shares of Avalo Therapeutics common stock. The award relates to performance stock units granted on August 19, 2025, which will fully vest on August 19, 2028 if specified performance goals remain achieved and Doyle continues in service through that vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Doyle Mittie

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	43,500	$0.00	--

Holdings After Transaction: Common Stock — 47,122 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 43,500 shares Price per share: $0.0000 per share Shares owned after: 47,122 shares +3 more

6 metrics

Shares granted 43,500 shares Common Stock grant/award on May 21, 2026

Price per share $0.0000 per share Recorded transaction price for grant

Shares owned after 47,122 shares Direct holdings following the transaction

PSU grant date August 19, 2025 Date performance stock units were granted

Performance certification date May 21, 2026 Compensation Committee certified performance goals

Vesting date August 19, 2028 PSUs scheduled to fully vest, subject to service

Key Terms

performance stock units, contingent right, performance goals, Compensation Committee, +1 more

5 terms

performance stock units financial

"Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025."

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

contingent right financial

"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals."

performance goals financial

"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals."

Performance goals are specific, measurable targets a company sets for financial results, operational milestones, or individual roles—examples include revenue, profit, production levels, or completion of a project. They matter to investors because meeting or missing these targets influences management pay, future forecasts, deal-related payments and market confidence; think of them as a scoreboard that helps outsiders judge whether the business is performing as promised.

Compensation Committee financial

"On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals."

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

vest financial

"As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doyle Mittie

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		A(1)		43,500	A	$0	47,122	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Avalo Therapeutics (AVTX) disclose for Mittie Doyle?

Avalo Therapeutics disclosed that Chief Medical Officer Mittie Doyle acquired 43,500 shares of Common Stock via a compensation-related grant. The award was recorded at a price of $0.0000 per share, indicating it was not an open-market purchase but part of her equity compensation.

How many Avalo Therapeutics (AVTX) shares does Mittie Doyle hold after this Form 4?

After this transaction, Mittie Doyle directly holds 47,122 shares of Avalo Therapeutics common stock. This total includes the 43,500 shares tied to performance stock units that became earned upon certification of performance goals and are scheduled to vest in the future.

What are the terms of the performance stock units reported for Avalo Therapeutics (AVTX)?

The performance stock units were granted on August 19, 2025, each representing a right to one share of common stock. On May 21, 2026, the Compensation Committee certified achievement of performance goals, and the related shares are set to fully vest on August 19, 2028, contingent on continued service.

Was the Avalo Therapeutics (AVTX) insider transaction a market purchase or a grant?

The transaction was a grant or award, not a market purchase. It is coded as a grant acquisition with a transaction price of $0.0000 per share, indicating Doyle received the shares as part of equity compensation rather than buying them in the open market.

When will the reported Avalo Therapeutics (AVTX) performance stock units fully vest?

The performance stock units associated with the 43,500 shares will fully vest on August 19, 2028. Vesting is contingent on the previously certified performance goals and Mittie Doyle’s continued service with Avalo Therapeutics through that vesting date, as described in the footnote.